Ajinomoto (2802) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
2 Feb, 2026Executive summary
Achieved record Q1 revenue of ¥365.5 billion, up 7.7% year-over-year, with business profit at ¥43.0 billion, up 7% excluding Forge acquisition impact.
Profit attributable to owners declined to ¥23.9 billion, 88% of prior year, mainly due to a temporary overseas withholding tax increase from fund repatriation.
Strategic investments increased company-wide expenses in Q1, aligned with the 2030 Roadmap, but full-year expenses are expected to remain within forecast.
No revision to the full-year forecast announced in May 2024.
Financial highlights
Sales revenue: ¥365.5 billion, 107.7% of Q1 last year; 102.3% excluding currency impact.
Business profit: ¥43.0 billion, up 0.5% year-over-year; up 7% excluding Forge.
Gross profit improved by ¥9.5 billion year-over-year, with gross profit at ¥133.4 billion.
Operating profit was ¥40.8 billion, up from ¥40.6 billion year-over-year.
Basic EPS was ¥46.98, down from ¥51.77 year-over-year.
Outlook and guidance
Full-year profit guidance unchanged; company expects gradual improvement in profit and sales from Q2 onward, especially in CDMO and functional materials.
Price hikes in domestic seasonings and coffee to support profit recovery in coming quarters.
Dividend forecast for FY2025 is ¥80.00 per share, up from ¥74.00 in FY2024.
Latest events from Ajinomoto
- AI-driven growth boosts ABF/ABF™ demand, margins, and capacity through innovation and investment.2802
Investor update3 Jul 2026 - Record sales and profit growth led to upward forecasts and increased shareholder returns.2802
Q2 20251 Jul 2026 - Record sales and profit highs, with raised full-year profit outlook and strong segment momentum.2802
Q3 202630 Jun 2026 - Global leader in amino acid science targets growth, health impact, and major sustainability gains.2802
Investor presentation30 Jun 2026 - Record profit and sales growth achieved, with further gains targeted amid managed global risks.2802
Q4 202613 May 2026 - Integrated sustainability and agri-food innovation drive growth and aim to double key solution sales by 2030.2802
Investor Day 20266 May 2026 - Governance, compensation, and management reforms drive long-term growth and value creation.2802
Investor update9 Apr 2026 - Record sales and profit growth led by overseas, healthcare, and currency gains amid cost pressures.2802
Q3 20259 Jan 2026 - Profit attributable to owners rose 2% as H1 results were flat, with strong H2 recovery expected.2802
Q2 202610 Dec 2025